Top Three Dividend Stocks To Enhance Your Portfolio

As global markets show resilience with cooling inflation and robust bank earnings propelling U.S. stocks higher, investors are keenly observing how these dynamics influence their portfolios. In this environment, dividend stocks can offer a stable income stream and potential growth, making them an appealing choice for enhancing portfolio stability amidst fluctuating market conditions.

Top 10 Dividend Stocks

Name	Dividend Yield	Dividend Rating
Peoples Bancorp (NasdaqGS:PEBO)	5.11%	★★★★★★
Wuliangye YibinLtd (SZSE:000858)	3.53%	★★★★★★
Padma Oil (DSE:PADMAOIL)	7.53%	★★★★★★
GakkyushaLtd (TSE:9769)	4.42%	★★★★★★
Guangxi LiuYao Group (SHSE:603368)	3.49%	★★★★★★
FALCO HOLDINGS (TSE:4671)	6.66%	★★★★★★
Citizens & Northern (NasdaqCM:CZNC)	5.89%	★★★★★★
Premier Financial (NasdaqGS:PFC)	4.93%	★★★★★★
DoshishaLtd (TSE:7483)	3.93%	★★★★★★
Southside Bancshares (NYSE:SBSI)	4.49%	★★★★★☆

Click here to see the full list of 1994 stocks from our Top Dividend Stocks screener.

Let's explore several standout options from the results in the screener.

Guangxi LiuYao Group (SHSE:603368)

Simply Wall St Dividend Rating: ★★★★★★

Overview: Guangxi LiuYao Group Co., Ltd is involved in the wholesale and retail of pharmaceutical products in China, with a market cap of CN¥6.85 billion.

Operations: Guangxi LiuYao Group Co., Ltd generates revenue through its pharmaceutical wholesale and retail operations in China.

Dividend Yield: 3.5%

Guangxi LiuYao Group's dividend appeal is underscored by its stable and reliable payouts over the past decade, with a current yield of 3.49%, placing it in the top 25% of CN market dividend payers. The company's dividends are well-covered by earnings (payout ratio: 25.4%) and cash flows (cash payout ratio: 44%). Recent earnings growth supports sustainability, while its price-to-earnings ratio of 7.7x suggests good value relative to peers and industry averages.

• Delve into the full analysis dividend report here for a deeper understanding of Guangxi LiuYao Group.
• Our valuation report here indicates Guangxi LiuYao Group may be undervalued.

Zhejiang Jiuzhou Pharmaceutical (SHSE:603456)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Zhejiang Jiuzhou Pharmaceutical Co., Ltd is a contract development and manufacturing organization operating in China and internationally, with a market cap of CN¥11.71 billion.

Operations: Zhejiang Jiuzhou Pharmaceutical Co., Ltd generates its revenue primarily through its operations as a contract development and manufacturing organization in both domestic and international markets.

Dividend Yield: 3.8%

Zhejiang Jiuzhou Pharmaceutical's dividend yield of 3.82% is among the top 25% in the CN market, yet its sustainability is questionable due to insufficient free cash flow coverage. The payout ratio of 64.6% indicates dividends are covered by earnings, but past volatility raises concerns about reliability. Despite trading at a favorable price-to-earnings ratio of 16.8x compared to the CN market, recent earnings declines highlight potential challenges for future dividend stability and growth prospects.

• Unlock comprehensive insights into our analysis of Zhejiang Jiuzhou Pharmaceutical stock in this dividend report.
• Our valuation report unveils the possibility Zhejiang Jiuzhou Pharmaceutical's shares may be trading at a discount.

Wuhan Keqian BiologyLtd (SHSE:688526)

Simply Wall St Dividend Rating: ★★★★☆☆

Overview: Wuhan Keqian Biology Co., Ltd is engaged in the research, development, production, sales, and technical services for animal epidemic prevention through veterinary biological products in China, with a market cap of CN¥6.04 billion.

Operations: Wuhan Keqian Biology Co., Ltd generates its revenue primarily from the veterinary biological products industry, amounting to CN¥902.14 million.

Dividend Yield: 3.3%

Wuhan Keqian Biology's dividend yield of 3.31% places it in the top 25% of CN market payers, supported by earnings and cash flow coverage with payout ratios at 67.1% and 69%, respectively. However, its four-year dividend history reveals volatility, including annual drops exceeding 20%. Despite trading below estimated fair value, recent sales and net income declines raise concerns about future dividend reliability amidst an unstable track record.

• Click here and access our complete dividend analysis report to understand the dynamics of Wuhan Keqian BiologyLtd.
• Upon reviewing our latest valuation report, Wuhan Keqian BiologyLtd's share price might be too pessimistic.

Taking Advantage

• Get an in-depth perspective on all 1994 Top Dividend Stocks by using our screener here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com